Insulet is trading at $172.25 (+4.40%) amid a broader healthcare sector bid and a rotation into defensive names, despite a lack of company-specific news.
- The move appears consistent with a favorable market backdrop for defensive stocks as capital rotates away from a weaker Nasdaq.
- No specific company announcements, earnings releases, or regulatory filings have been identified to account for the strong opening move.